Lerdelimumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | TGF beta 2 |
| Identifiers | |
| CAS Number | 285985-06-0 |
| ATC code | none |
Lerdelimumab (CAT-152) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.[1]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ "Lerdelimumab: 6B1, Anti-TGF-Beta-2 Monoclonal Antibody". Drugs in R&D. Adis International. 3 (2): 106–108. 1 February 2002.
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
